--- title: "Valneva registers resale of up to 31,787,634 ordinary shares by selling holders" url: "https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-04" section: "Financings" tickers: "EURONEXT:VLA" source: "https://www.sec.gov/Archives/edgar/data/1836564/000199937126012100/valneva-f3_060426.htm" summary: "Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it" --- By the aibio.space news desk. Sources - [Valneva SE F-3 (2026-06-04)](https://www.sec.gov/Archives/edgar/data/1836564/000199937126012100/valneva-f3_060426.htm) - [Valneva SE 20-F (2026-03-17): business](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/valn-20251231.htm) - [Valneva SE financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) [VLA](https://aibio.space/companies/valneva/) 2026-06-04 # Valneva registers resale of up to 31,787,634 ordinary shares by selling holders Tickers [VLA](https://aibio.space/companies/valneva/) Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale. ## Key facts - **Company**: Valneva SE (EURONEXT: VLA) - **News type**: Financings - **Primary source**: [Valneva SE F-3 (2026-06-04)](https://www.sec.gov/Archives/edgar/data/1836564/000199937126012100/valneva-f3_060426.htm) *A red price chart on a screen. CC0, via rawpixel. The picture shows the field, not the companies named.* Valneva SE filed a Form F-3 registration statement with the Securities and Exchange Commission on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares by selling securityholders. The shares may be held as American Depositary Shares, or ADSs. Each ADS represents two ordinary shares. The ADSs trade on the Nasdaq Global Select Market as VALN, and the ordinary shares trade on the regulated market of Euronext in Paris as VLA. The filing does not name the selling holders. It says their names, and the number of shares each sells, would be set out in a prospectus supplement where required. ## What is being registered The total has two parts. The first is 15,893,817 issued and outstanding ordinary shares. The second is 15,893,817 ordinary shares that can be issued when holders exercise warrants, which the filing calls ABSA Warrants. The holders acquired these securities under the securities purchase agreement dated April 29, 2026, the same deal Valneva described in a Form 6-K filed on April 30. Valneva is registering the resale to meet its obligations under a registration rights agreement of the same date. The prospectus is marked as subject to completion. The selling holders may not sell until the registration statement is declared effective by the SEC. ## Proceeds, costs and pricing Valneva says it will not receive any proceeds from the resale. The filing does say the company could receive up to €47 million if the ABSA Warrants are exercised in full for cash, and that it intends to use any such money for manufacturing, commercialization, and research and development of its products and product candidates, working capital and general corporate purposes. The selling holders will bear any underwriting fees, commissions and discounts on their sales, and any transfer taxes. Valneva will pay all other registration costs. The holders may sell at prevailing market prices, at prices tied to those prices, or at negotiated prices. On June 3, 2026, the last reported sale price was $5.58 per ADS on Nasdaq. The ordinary shares closed at €2.378 on Euronext Paris. That close is above the €2.33 price per share-and-warrant unit in the April deal, and below the €2.96 strike on the warrants. ## Who arranged it The F-3 names no underwriter, placement agent or financial advisor for the resale. It names counsel to the company. Jones Day of Paris will pass on the validity of the shares and certain French-law matters, and Cooley LLP of Boston represents Valneva on certain U.S.-law matters. Marc Recht and Courtney Thorne of Cooley and Florent Bouyer of Jones Day are listed to receive copies of communications. ## Company background The registration statement has a section on documents incorporated by reference. Valneva's annual report on Form 20-F for 2025, filed on March 17, 2026, shows a net loss of €115.2 million, against €12.2 million in 2024. Cash used in operations fell to €52.9 million from €67.2 million. Cash and cash equivalents were €109.7 million at the end of 2025, down from €168.3 million a year earlier. The figures do not explain why the net loss rose while cash used in operations fell. The company also said it voluntarily withdrew the Biologics License Application and the Investigational New Drug application for IXCHIQ, its chikungunya vaccine, in January 2026. The Lyme candidate, VLA15 in the annual report and LB6V under the warrant terms, is a Phase 3 vaccine developed with Pfizer. The 20-F says vaccinations in the VALOR field trial were completed in July 2025, with monitoring through the end of 2025. The F-3 reports no results from that trial. ## What the filing leaves out For existing holders, the registration means that up to 31,787,634 shares could reach the market, and the filing does not say how quickly the selling holders plan to sell. The resale does not change Valneva's cash position on its own. It does mean the company's share count could rise sharply if the warrants are exercised, and that the cash from those warrants depends on a share price above €2.96. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story VLA Valneva SE EURONEXT · France Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Valneva registers resale of up to 31,787,634 ordinary shares by selling holders", 2026-06-04, https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/